Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral hypoglycemic agents.

H E Lebovitz1

  • 1Clinical Research Center, SUNY Health Science Center, Brooklyn.

Primary Care
|June 1, 1988
PubMed
Summary
This summary is machine-generated.

Oral hypoglycemic agents (OHAs) have a complex history in treating non-insulin-dependent diabetes mellitus (NIDDM). Initially successful, their use declined due to safety concerns but has since resurged for managing hyperglycemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

Diabetes, obesity & metabolism·2015
Same author

Treatment of Patients with Obese Type 2 Diabetes with Tantalus-DIAMOND® Gastric Electrical Stimulation: Normal Triglycerides Predict Durable Effects for at Least 3 Years.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2015
Same author

Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm.

Diabetic medicine : a journal of the British Diabetic Association·2013
Same author

New treatments of diabetes: the beta-amylin agonists.

Annales d'endocrinologie·2008
Same author

Diagnosis, classification, and pathogenesis of diabetes mellitus.

The Journal of clinical psychiatry·2002
Same author

Oral therapies for diabetic hyperglycemia.

Endocrinology and metabolism clinics of North America·2001
Same journal

Primary Care at the Center of America's Mental Health Landscape.

Primary care·2026
Same journal

We Care, and We Will Listen.

Primary care·2026
Same journal

Addressing Sexual Health in Primary Care.

Primary care·2026
Same journal

Diagnosis and Management of Eating Disorders in Adolescents and Young Adults.

Primary care·2026
Same journal

Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment.

Primary care·2026
Same journal

Nonpharmacologic Management of Insomnia Disorder in Primary Care.

Primary care·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology
  • Medical History

Background:

  • Non-insulin-dependent diabetes mellitus (NIDDM) management has evolved significantly.
  • Oral hypoglycemic agents (OHAs) have played a pivotal role in NIDDM treatment strategies.
  • The historical trajectory of OHA use reflects changing therapeutic paradigms and safety evaluations.

Purpose of the Study:

  • To review the historical development and utilization of oral hypoglycemic agents in NIDDM.
  • To analyze the factors influencing the rise, fall, and resurgence of OHA use.
  • To provide context for the current role of OHAs in diabetes management.

Main Methods:

  • Historical review of scientific literature and clinical trial data.
  • Analysis of key events and publications impacting OHA prescribing trends.

Related Experiment Videos

  • Examination of the University Group Diabetes Program (UGDP) findings and their consequences.

    • Main Results:

    • Oral hypoglycemic agents (e.g., sulfonylureas) gained prominence in the late 1950s for NIDDM.
    • The University Group Diabetes Program (UGDP) study raised safety concerns, leading to a decline in OHA use.
    • Subsequent research and re-evaluation have re-established OHAs as valuable tools for hyperglycemia management in NIDDM.

    Conclusions:

    • The history of OHAs in NIDDM is marked by periods of widespread adoption, controversy, and renewed acceptance.
    • Understanding this history is crucial for appreciating the current evidence-based use of OHAs.
    • OHAs remain important agents in the multifaceted management of hyperglycemia in NIDDM patients.